Lu AF28996 in Chinese People With Parkinson's Disease
Tests how safe Lu AF28996 is, and how the body handles it, in Parkinson's disease.
Plain-language title generated from the registry record
Registry title: A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD)
Key facts
- Where
- Beijing, Chengdu, and Shanghai Shi, ChinaSee the 4 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 35 and 85 years old?
Source: NCT07513441, who can take part
Where in China
- Beijing TiantanHospital, CapitalMedical UniversityBeijing, ChinaTaking people
- Xuanwu Hospital, Capital Medical UniversityBeijing, ChinaTaking people
- West China Hospital，Sichuan UniversityChengdu, ChinaTaking people
- Fudan University - Huashan Hospital - Institute of UrologyShanghai Shi, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- H. Lundbeck A/S
- Trial code
- NCT07513441
- Record updated
- 10 August 2026
- Original description
The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.Read full original descriptionShow less
Interventional, Open-label, Trial Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AF28996 in Chinese Men and Women With Parkinson's Disease
The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.
Inclusion: The participant is Chinese, defined as having four Chinese grandparents being born in China; The participant is diagnosed with idiopathic Parkinson's disease (consistent with the United Kingdom PD Society Brain Bank Criteria for the Diagnosis of PD); The participant's Modified Hoehn and Yahr score is ≥2 and ≤4 (in OFF) and ≤3 in the ON state; The participant experiences well recognizable and predictable motor fluctuations in the awake time including predictable morning OFF episodes causing clinically significant disability during the last 3 months prior to screening, as evaluated by the investigator.
Exclusion: The participant has received oral or transdermal dopamine agonist treatment ≤4 weeks prior to screening; The participant has received Traditional Chinese Medicine treatment ≤4 weeks prior to screening; Note: Other protocol-defined inclusion and exclusion criteria may apply; The participant has undergone a neurosurgical intervention for Parkinson's disease (such as pallidotomy, thalamotomy, foetal or stem cell transplantation or deep brain stimulation); The participant has any other disorder for which the treatment takes priority over treatment of Parkinson's disease or is likely to interfere with trial treatment or impair treatment compliance.